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The chemogenetic technology DREADD affords a minimally invasive means to reversibly and remotely control the activity of DREADD-expressing cells through the systemic delivery 
of DREADD ligands1. Several DREADDs exist, derived from mus-
carinic or κ-opioid receptors1,2, and they have been widely adopted 
for neuroscience research3. Muscarinic receptor DREADDs 
are the most widely used and can be activated by CNO (Fig. 1d, 
right). Activation of a modified human M3 muscarinic receptor 
(hM3Dq) enhances neuronal activity, while a modified M4 receptor 
(hM4Di) silences it. CNO-activated DREADDs have been success-
fully applied in a variety of in vitro and in vivo contexts, including 
in nonhuman primate studies to modify neural network activity4  
and behavior5–7.
Since CNO has modest brain permeability, relatively large sys-
temic doses may be required for DREADD activation. Moreover, 
CNO can be metabolized to clozapine (Fig. 1a, right), which is a 
potent, brain-permeable DREADD agonist1,8. CNO metabolism to 
clozapine is non-negligible in rodents8,9 and in monkeys10. In addi-
tion to activating DREADDs, clozapine potently binds to many 
endogenous receptors and transporters11; thus, CNO or clozapine 
can produce confounding off-target side effects. Although alterna-
tive DREADD agonists, such as compound 21 (C21) (Fig. 1d, left) 
and perlapine12,13, have been recently developed, they require rela-
tively large systemic doses to activate DREADDs in vivo and may 
have off-target actions13. Given the broad utility and popularity 
of muscarinic-based DREADDs, the development of a selective, 
high-affinity, metabolically stable and brain-penetrable DREADD 
agonist is important.
Here, we identified a suitable DREADD agonist that we have 
named DCZ (11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)
diazepine) (Fig. 1a, left), which is derived from our previous stud-
ies of DREADD ligands for muscarinic-based DREADDs12. We 
became aware of DCZ as it had been previously reported to have 
substantially lower affinity for dopaminergic (D1 and D2) and sero-
tonergic (5-HT2A and 5-HT2C) receptors than clozapine14. We deter-
mined that DCZ has 100-fold improved affinity and greater agonist 
potency for hM3Dq and hM4Di relative to CNO or C21, with 
reduced off-target binding compared to clozapine in vitro. Using 
positron emission tomography (PET), we demonstrate that DCZ is 
rapidly brain penetrable, is apparently selective and that doses for 
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The chemogenetic technology designer receptors exclusively activated by designer drugs (DREADDs) afford remotely revers-
ible control of cellular signaling, neuronal activity and behavior. Although the combination of muscarinic-based DREADDs with 
clozapine-N-oxide (CNO) has been widely used, sluggish kinetics, metabolic liabilities and potential off-target effects of CNO 
represent areas for improvement. Here, we provide a new high-affinity and selective agonist deschloroclozapine (DCZ) for 
muscarinic-based DREADDs. Positron emission tomography revealed that DCZ selectively bound to and occupied DREADDs in 
both mice and monkeys. Systemic delivery of low doses of DCZ (1 or 3 μg per kg) enhanced neuronal activity via hM3Dq within 
minutes in mice and monkeys. Intramuscular injections of DCZ (100 μg per kg) reversibly induced spatial working memory 
deficits in monkeys expressing hM4Di in the prefrontal cortex. DCZ represents a potent, selective, metabolically stable and 
fast-acting DREADD agonist with utility in both mice and nonhuman primates for a variety of applications.
DREADD occupancy are 20-fold and 60-fold lower than CNO and 
C21, respectively. Finally, we demonstrate that DCZ is capable of 
rapidly (<10 min post-injection) activating hM3Dq and hM4Di in 
both mice and monkeys without discernible off-target action. Thus, 
DCZ represents a potent and selective chemogenetic actuator for 
muscarinic-based DREADDs in mice and primates in a variety of 
in vitro and in vivo contexts with high translational potential.
Results
DCZ selectively binds to DREADDs in vitro and in vivo. We first 
assessed the binding affinities of DCZ to hM3Dq and hM4Di and 
compared them to those of clozapine, CNO and C21 using com-
petition binding assays with [3H]quinuclidinyl benzilate (QNB) on 
HEK293T cells. DCZ had nanomolar affinity for [3H]QNB-labeled 
hM3Dq and hM4Di (inhibition constant (Ki) values of 6.3 nM for 
hM3Dq and 4.2 nM for hM4Di), which was comparable to clo-
zapine (hM3DqKi = 5.9 nM, hM4DiKi = 0.89). CNO and C21 were about 
100-fold and 50-fold weaker, respectively (CNO: hM3DqKi = 680 nM, 
hM4DiKi = 360 nM; C21: hM3DqKi = 850 nM, hM4DiKi = 180 nM) (Table 1).
Unlike clozapine (Fig. 1c; Supplementary Table 1), DCZ had negli-
gible affinities for a large number of tested G protein-coupled recep-








































































































































































































































































































































































Fig. 1 | DCZ selectively binds to DREADDs. a, Chemical structure of DCZ and clozapine. b,c, Binding affinities of DCZ and clozapine to DREADDs and 
endogenous receptors, channels and transporters. Ki values are the average of at least three triplicate experiments with standard deviation values that are 
threefold less than the average. The values are also shown in Table 1 and Supplementary Table 1. d, Chemical structure of C21 and CNO. e, Illustration of 
the location of viral vector injections. AAV2-CMV-hM4Di and AAV2-CMV-KORD (as control) were injected into the right and left putamen, respectively. 
D, dorsal; L, left; R, right; V, ventral. f, Illustration of in vivo PET imaging with [11C]DCZ in monkeys. g–i, Representative PET imaging data obtained from 
monkey 209. g, Left: coronal section of a PET image of [11C]DCZ SUVs (regional radioactivity (Bq cm–3) × body weight (g)/injected radioactivity (Bq)) 
between 30 and 90 min from injection. Right: the time course of regional uptake (mean ± s.d., N = 3 scans) of [11C]DCZ at the hM4Di-expression region in 
the putamen (hM4Di-PUT), a control region in the contralateral putamen (Ctrl-PUT), and the cerebellum. h, Same as g but with [11C]clozapine (N = 4). i, 
Same as g but with [11C]CNO (N = 1). Scale bars, 5 mm.
and relatively low affinities for a few endogenous receptors, includ-
ing muscarinic acetylcholine (hM1Ki = 83 nM, hM5Ki = 55 nM) and 
serotonin receptors (5-HT2AKi = 87 nM) (Fig. 1b; Supplementary 
Table 1), which represents at least an eightfold antagonist binding 
selectivity for muscarinic DREADDs over its most potent endog-
enous targets.
We next examined whether DCZ enters the brain and binds to 
DREADDs in vivo. Here, we performed PET with radiolabeled DCZ 
([11C]DCZ) in two monkeys (see Supplementary Table 2 for a sum-
mary of the monkeys used in these experiments), which had received 
an adeno-associated virus type 2 vector (AAV2-CMV-hM4Di) 
injection that resulted in neuron-specific expression of hM4Di6 
in the right putamen. An AAV2 control vector carrying the 
κ-opioid-based DREADD (AAV2-CMV-KORD) was injected into 
the left putamen (Fig. 1e) as it does not bind DCZ (not shown)2. 
Six weeks later, when stable expression is predicted6, the monkeys 
were scanned via PET after intravenous (i.v.) administration of a 
microdose of [11C]DCZ (Fig. 1f). The results revealed rapid brain 
penetrance of [11C]DCZ with high radioactive accumulation in the 
hM4Di-expressing putamen (standardized radioligand uptake val-
ues (SUVs) at 85–90 min of 6.3 ± 0.4 for monkey 209 and 4.5 ± 0.8 
for monkey 212 (mean ± s.d.)). Accumulation in the contralateral 
putamen was insignificant (2.4 ± 0.7 for monkey 209, 1.7 ± 0.3 for 
monkey 212) (see Fig. 1g for representative findings), which is in 
agreement with the high selectivity of DCZ for DREADDs in vitro. 
Low DCZ uptake was visible in surrounding cortical areas, which 
potentially reflects DCZ binding to endogenous receptors with low 
affinities. Using a single subject (monkey 209), brain permeability 
and selectivity of DCZ were then directly compared to clozapine 
and CNO, two DREADD agonists whose radiolabeled forms were 
available; C21 radiolabeled with [11C] was unavailable. Consistent 
with our previous study6, PET imaging with microdoses of [11C]clo-
zapine showed moderate uptake at the control putamen and cortical 
areas (Fig. 1h, left), which likely reflects its high binding affinity for 
many endogenous receptors (Fig. 1c; Supplementary Table 1), and 
increased uptake at the hM4Di-expressing putamen region, which 
presumably reflects clozapine binding to hM4Di (Fig. 1h, left). PET 
imaging with [11C]CNO revealed a low brain signal, which indicates 
modest brain permeability (Fig. 1i). Indeed, the concentration of 
[11C]CNO in the entire brain at 30 min was 0.14% of the injected 
dose, which was >40-fold lower than that of [11C]DCZ or [11C]clo-
zapine (5.9% and 7.0%, respectively).
Dynamic regional radioactivity reflects radioligand localiza-
tion in the vascular system and brain tissue in the initial phase and 
ligand binding to tissue in the later phase. Here, the [11C]DCZ signal 
at the target region continued to increase, nearly reaching a plateau 
90 min after radioligand injection, whereas the signal on the contra-
lateral side moderately increased and then rapidly decayed (Fig. 1g, 
right). These regional differences in radioactivity were abolished by 
pretreatment with unlabeled DCZ (1 mg per kg, i.v.) (Supplementary 
Fig. 1a), and therefore reflect displaceable ligand binding. We quan-
tified specific [11C]DCZ binding to tissue using the cerebellum as 
a reference region, where radioligand kinetics were unchanged by 
pretreatment (Supplementary Fig. 1a). On the parametric image 
representing specific binding, BPND (that is, the binding potential 
relative to non-displaceable uptake), high [11C]DCZ was localized 
to the hM4Di-vector-injected side of the putamen, which corre-
sponds to the area where anti-hM4 post-mortem immunolabeling 
was found (Fig. 2a,b; Supplementary Fig. 2a), thus confirming that 
[11C]DCZ binds to hM4Di in vivo. In addition, high [11C]DCZ bind-
ing was found in the projection target of the putamen—the sub-
stantia nigra—reflecting hM4Di expression at the axon terminals 
as confirmed by immunohistochemistry (Supplementary Fig. 2b).
To verify in vivo DCZ binding to DREADDs in mice, we per-
formed [11C]DCZ PET imaging with a transgenic mouse expressing 
hM4Di under the control of the neuron-specific Thy-1 promoter15. 
[11C]DCZ uptake in the striatum and cortex was upregulated in 
transgenic mice compared with wild-type mice (Supplementary 
Fig. 1b, left versus center). In the parametric image, high [11C]DCZ 
binding was observed in the frontal and parietal cortices, hippocam-
pus and striatum, which is consistent with high hM4Di expression 
(as confirmed by immunofluorescence). In contrast, no discern-
ible binding was seen in wild-type mouse brains (Supplementary 
Fig. 2c,d), which implies that there is low off-target binding at this 
dose. Taken together, our PET results suggest that DCZ rapidly 
enters the brain and selectively binds to hM4Di expressed in both 
mice and monkeys.
Systemic low-dose DCZ occupies hM4Di DREADD in vivo. In 
previous chemogenetic studies, a range of systemic CNO doses were 
used to obtain behavioral effects, which suggests that the required 
dose may vary according to the target neuronal population, the type 
of DREADD and the level/localization of expression, among other 
factors16. Similar to most drugs, at pre-saturation, a higher agonist 
dose affords a stronger chemogenetic effect, but also has greater 
off-target potential. Although DCZ has lower levels of off-target 
binding than clozapine, finding the effective and safe dose range for 
systemic DCZ administration is critical for studies seeking selective 
Table 1 | Binding affinities of DCZ, clozapine and CNO to DREADDs and native muscarinic receptors
Compound Mean values hM3Dq hM3 hM4Di hM4
DCZ Ki (nM) 6.3 230 4.2 210
pKi (± s.e.m) 8.20 (± 0.15) 6.63 (± 0.06) 8.38 
(± 0.27)
6.68 (± 0.04)
Clozapine Ki (nM) 5.9 21 0.89 10
pKi (± s.e.m) 8.23 (± 0.26) 7.69 (± 0.14) 9.05 
(± 0.13)
7.98 (± 0.10)
CNO Ki (nM) 680 2,600 360 3,700
pKi (± s.e.m) 6.17 (± 0.07) 5.59 (± 0.06) 6.44 
(± 0.03)
5.43 (± 0.18)
C21 Ki (nM) 850 270 178a 3,631a
pKi (± s.e.m) 6.07 (± 0.06) 6.57 (± 0.15) 6.75 
(± 0.26)
5.44 (± 0.11)
The average of at least three duplicate experiments with standard deviation values that are threefold less than average are shown. aData from Thompson et al.13. Radioligand binding assays were performed 
with QNB on HEK293T cells. The average [3H]QNB concentrations were 0.8 nM for hM3/hM4 and 2.0 nM for hM3Dq/hM4Di.
DREADD manipulation. We previously used PET imaging to mea-
sure the relationship between CNO dose and the degree of hM4Di 
receptor occupancy, and provided a reasonable upper CNO dose 
(≤10 mg per kg); these doses successfully induced behavioral altera-
tions in monkeys, while higher doses did not increase occupancy6. 
To quantify the relationship between DCZ dose and hM4Di occu-
pancy, we performed [11C]DCZ PET scans 15 min after i.v. bolus 
injection of non-radiolabeled DCZ (10, 30, 100 and 1,000 μg per kg) 
in two monkeys (Fig. 2c). With increasing doses of non-radiolabeled 
DCZ, specific binding of [11C]DCZ decreased at the hM4Di vector 
injection site, while the decrease at the contralateral control site was 
limited. We determined the occupancy as a reduction of BPND at the 
target region over the control side relative to baseline. The relation-
ship between the occupancy of hM4Di and DCZ dose was fit to a 
Hill equation with a coefficient (n) equal to approximately 1 (Fig. 2d; 
Methods), which indicates that DCZ binds non-cooperatively. The 
data also suggest that a reasonable dose range of DCZ for monkey 
studies is ≤100 μg per kg: occupancy increases linearly based on the 
logarithmic dose in this range, while higher doses would contribute 
to a minimal increase in occupancy as predicted based on standard 
receptor–ligand relationships.
Additional occupancy studies with CNO and C21 revealed that 
higher doses were required to occupy hM4Di (Fig. 2d). The dose–
occupancy relationship of C21 indicated its binding property (Hill 
coefficient, n = 1) was similar to DCZ, while that of CNO (n = 0.44) 
might reflect complex kinetics of CNO metabolism and excretion. 
We estimated that the dose required for 50% occupancy (ED50) for 
DCZ and compared it with those for CNO and C21. The ED50 for 
DCZ was 25 μg per kg, which is 24-fold and 60-fold smaller than for 
CNO (630 μg per kg) and C21 (1,500 μg per kg), respectively (Fig. 2d).
Pharmacokinetic (PK) studies demonstrated that DCZ admin-
istration (100 μg per kg, i.v.) yielded a maximum concentra-
tion of DCZ in the cerebrospinal fluid (CSF; ~10 nM) at 30 min 
post-injection, which was maintained for at least 2 h in monkeys 
(Fig. 3a, right). A similar level of DCZ in CSF (~10 nM) was observed 
at 60 min and later following intramuscular (i.m.) administration 
(Fig. 3b, right). The DCZ concentration was higher than its Ki 
value for hM4Di in antagonist radioligand binding studies (4.2 nM; 
Table 1) and far below its Ki value for numerous endogenous chan-
nels, receptors and transporters (>50 nM; Fig. 1b). We did not 
detect any major metabolites of DCZ in the CSF (Fig. 3a,b, right) in 
monkeys. Collectively, these results suggest that a low systemic dose 
of DCZ (that is, 100 μg per kg) affords a sufficient concentration of 
DCZ for hM4Di DREADD binding in vivo for at least 2 h without 
the detection of metabolites (Fig. 3d) in monkeys.
We also found that DCZ was rapidly available in the mouse brain 
following intraperitoneal (i.p.) administration (Fig. 3c). The DCZ 
concentration was ~6-7 nM in CSF and ~100 nM in brain tissue 
30 min after administration (Fig. 3c). As the free (unbound) frac-
tion of drug is key for determining the amount of drug that can bind 
a target protein, we quantified brain protein binding. Such analysis 
revealed that the fraction of DCZ unbound to mouse brain tissue 
was about 7.5% (at 1 μM test concentration), which indicates that 
a major fraction of DCZ binds nonspecifically to brain proteins, as 
previously described for many CNS-active compounds17,18. The free 
DCZ concentration in CSF was comparable in mice (6–7 nM) and 
monkeys (~10 nM). Unlike the PK profiles in monkeys, DCZ con-
centrations in mice rapidly declined and were undetectable at 2 h 
in both brain tissue and CSF. It is unsurprising that the PK prop-
erties of DCZ differ in mice and monkeys, as species differences 
in the PK properties of CNS-active drugs are well documented19. 
Although C21, the desmethyl metabolite of DCZ (Fig. 3d), was 
abundant in plasma, C21 was negligible in CSF (<0.2 nM, ~3% of 
DCZ at 30 min) (Fig. 3c).
DCZ is a potent in vitro DREADD agonist. We next quantified the 
in vitro agonist activity of DCZ for muscarinic-based DREADDs 
and compared its potency with several previously reported agonists. 
We first performed in vitro bioluminescence resonance energy 
transfer (BRET) assays, which directly measure agonist-induced 
G protein dissociation, the most proximal signaling event down-
stream of GPCR activation, with minimal potentiation due to 
so-called ‘receptor reserve’ or downstream signal amplification20. 
Using BRET-based assays, DCZ was a potent hM3Dq agonist 
(EC50 = 0.13 nM; 95% confidence interval (CI) = 0.09–0.21)—com-
parable to clozapine (hM3DqEC50 = 0.09 (CI = 0.06–0.15) nM)—and 
about 40-fold and 100-fold more potent than C21 (hM3DqEC50 = 5.2 
(CI = 3.7–7.3) nM) and CNO (hM3DqEC50 = 15 (CI = 8.8–25) nM), 
respectively (Fig. 4a). DCZ was also a potent agonist for hM4Di 
(hM4DiEC50 = 0.081 (CI = 0.042–0.16) nM), which is again compara-
ble to clozapine (hM4DiEC50 = 0.051 (CI = 0.027–0.097) nM), but with 
about 30-fold and 90-fold greater potency than C21 (hM4DiEC50 = 2.6 
(CI = 1.6–4.4) nM) and CNO (hM4DiEC50 = 7.3 (CI = 3.6–15) nM) 
(Fig. 4b), respectively.
Superior in vitro potency of DCZ over C21 and CNO was also 
demonstrated in a calcium mobilization assay for hM3Dq12 and for 
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Fig. 2 | [11C]DCZ PET visualizes DREADD expression and measures the 
agonist dose–occupancy relationship. a, A coronal section of a parametric 
[11C]DCZ PET image of specific binding (BPND) overlaying an MR image of 
monkey 209 expressing hM4Di in the putamen. b, An anti-hM4 staining 
section corresponding to the image in a. Scale bars, 5 mm (a and b).  
c, Illustration of the occupancy study. Monkeys underwent a [11C]DCZ 
PET scan 15 min after i.v. injection of non-radiolabeled DCZ, CNO or C21. 
d, Occupancy of hM4Di plotted as a function of DCZ, CNO or C21 dose. 
Filled and open circles represent data obtained from monkeys 209 and 212, 
respectively. Dotted curves are the best-fit Hill equation for the data. ED50 
indicates the agonist dose inducing 50% occupancy. Hill coefficient (n) and 
coefficient of determination (R2) values are as follows: DCZ: n = 1, R2 = 0.99; 
CNO: n = 0.44, R2 = 0.96; C21: n = 1, R2 > 0.99.
no effect of DCZ was observed in the absence of DREADD expres-
sion (Supplementary Fig. 3a–c). To further evaluate potential DCZ 
off-target agonist actions, we assessed its agonist activity at 318 
endogenous GPCRs using an arrestin recruitment assay platform21. 
While DCZ was a potent agonist for hM3Dq and hM4Di, it did 
not display noticeable agonistic activity for any of the 318 tested 
wild-type GPCRs at <10 nM, the typical concentration that could 
be reached with the dose used (Supplementary Fig. 3d–l). Taken 
together, these results imply that the agonism of DCZ is apparently 
selective for hM3Dq and hM4Di.
DCZ selectively and rapidly enhances neuronal activity via the 
hM3Dq DREADD in vivo. We next examined the agonist actions 
of DCZ on DREADDs and its time course in vivo using two-photon 
calcium imaging in mice expressing hM3Dq. AAV vectors carry-
ing the GCaMP6s genes (AAV-DJ-rSyn-GCaMP6s) and hM3Dq 
construct (AAV2-CMV-hM3Dq) were co-injected into the barrel 
cortex (Fig. 4c). At 28 days post-injection, in vivo hM3Dq expres-
sion was visualized by [11C]DCZ PET as a high radioligand bind-
ing region at the injection site (Fig. 4d; Supplementary Fig. 1b, 
right). Given its high potency in vitro, we used DCZ at a dose of 
1 μg per kg. Shortly after i.p. injections of DCZ, transient and repeti-
tive increases in fluorescence signals were observed in the soma of 
hM3Dq-expressing neurons (Fig. 4e,f). On average, relative fluo-
rescence signal changes from baseline (ΔF/F) rapidly increased 
(τ = 3 min) and became significant at 5 min post-injection (P < 0.01, 
one-way analysis of variance (ANOVA) with post hoc Dunnett 
test). ΔF/F values achieved their peak at about 10 min, plateaued 
for at least 150 min, and then returned to the baseline levels at 4 h 
post-injection (Fig. 4g, red; P = 0.53). Vehicle injection did not 
change the activity of the same neuronal population (Fig. 4g, cyan). 
The DCZ-induced increases in fluorescence signals were appar-
ently mediated by hM3Dq because DCZ did not alter the signal in 
mice without DREADD expression (Fig. 4g, black). Although DCZ 
induced strong activity changes, it did not cause long-term apparent 
desensitization to hM3Dq-positive neurons after recovery, since the 
neurons demonstrated a reproduced chemogenetic activation by 
the second DCZ dose and a replicated response to whisker stimula-
tion (Supplementary Fig. 4).
To compare the in vivo agonist efficacy of DCZ with those of 
other ligands, we used 100-fold higher doses (100 μg per kg, i.p.) of 
CNO and C21 because they require higher doses to occupy and acti-
vate DREADDs (Figs. 2d and 4a). Although administration of CNO 
and C21 increased ΔF/F of hM3Dq-expressing neurons, their peak 
values were less than 40% of that of DCZ (Fig. 4g, blue and purple). 
Moreover, the kinetics of CNO were relatively slow (τ = 17 min), 
with the upward trend lasting for 30 min post-injection and then 
plateauing (Fig. 4g, blue), as observed in a previous electrophysi-
ological study22. While C21 quickly increased ΔF/F (τ = 4 min), 
the increase became significant only at 30 min post-injection or 
later (Fig. 4g, purple). Thus, DCZ rapidly and reversibly activates 
hM3Dq-expressing neuronal populations in mice in vivo, with 
higher efficacy and potency than C21 or CNO.
Rapid and reversible chemogenetic neuronal control was also 
observed in monkeys after systemic DCZ administration. A total 
of four monkeys were injected with AAV2-CMV-hM3Dq into the 
unilateral amygdala (Fig. 5a; one used for electrophysiology and 
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Fig. 3 | Time–concentration profiles of DCZ and its metabolites in monkeys and mice. a, Plasma and CSF concentrations of DCZ and its major 
metabolites (C21 and DCZ-N-oxide) following i.v. injection (100 μg per kg). Data were collected from four monkeys and are shown as the mean ± s.e.m. The 
inset shows the full-scale plot. b, Same as a, but following i.m. injection. c, Plasma, brain and CSF concentrations of DCZ, C21 and DCZ-N-oxide following 
i.p. injection of DCZ (100 μg per kg). Data were collected from three or four mice and are shown as the mean ± s.e.m. d, Major routes of DCZ metabolism 
leading to C21 and DCZ-N-oxide and their structures.
post-injection, in vivo hM3Dq expression was visualized by [11C]
DCZ PET as a high radioligand binding region at the injection 
site (Fig. 5b), which was confirmed by immunohistochemistry 
(Supplementary Fig. 5). We recorded local field potentials (LFPs) 
from the hM3Dq-positive area of one monkey using a multisite 
linear probe, the location of which was confirmed by computer 
tomography (CT)–PET fusion images (Fig. 5b). To the best of our 
knowledge, there have been no prior reports of a monkey chemo-
genetic study using hM3Dq. Therefore, we applied the same dose of 
DCZ (1 μg per kg) as in mice to avoid potential risks of excitotox-
icity or seizure due to excessive neuronal activation. In the amyg-
dala, LFP gamma band activity, which correlates with firing of local 
populations of neurons23, increased significantly from baseline by 
administration of DCZ (t(26) = 7.3, P = 8.7 × 10−8, paired t-test), but 
not by vehicle (t(25) = 0.28, P = 0.78; Fig. 5c,d). As control, when 
we placed an electrode outside the hM3Dq-positive sites, significant 
changes in gamma power were not observed after DCZ adminis-
tration (t(10) = 0.46, P = 0.65; Fig. 5d). LFP gamma power rapidly 
increased (τ = 4 min) from baseline and became significant at 5 min 
after DCZ administration, and this significant increase lasted for 
at least 45 min (P < 0.01, one-way ANOVA with post hoc Dunnett 
test; Fig. 5e).
DCZ selectively induces hM3Dq-mediated metabolic activ-
ity. We next performed a PET study with [18F]fluorodeoxyglucose 
(FDG) to examine whether DCZ induces dose-dependent and 
DREADD-selective changes in regional brain glucose metabolism, 
an index of brain neuronal/synaptic activation24–26. Three monkeys 
expressing hM3Dq in the unilateral amygdala underwent [18F]
FDG PET imaging following systemic DCZ or vehicle injection 
DCZ (1 µg per kg)




























DCZ (1 µg per kg)
non-hM3Dq
*
* * * *
**
1501200 30 60 90 4 6
(h)




* ** ** * *












































































Fig. 4 | In vitro potency and in vivo efficacy of DCZ for DREADDs. a,b, BRET-based estimation of agonist potency and efficacy at hM3Dq and hM4Di 
in HEK293T cells. Shown are the mean ± s.e.m. of N = 3 independent biological replicates (each of which had duplicate technical replicates) of dose–
response curves for hM3Dq using a Gq-based BRET sensor and hM4Di using a Gi1-based BRET sensor. c, Illustration of two-photon calcium imaging and 
location for co-injection of AAV2-CMV-hM3Dq and AAV-DJ-rSyn-GCaMP6s. d, A parametric image of specific binding of [11C]DCZ overlaying an MR 
image. e, Time-averaged two-photon images of GCaMP6 of pre-injection (left) and 5 min post-DCZ injection (1 μg per kg, i.p.) (right). Arrowheads indicate 
the neurons measured. f, Raw fluorescence signals in 14 representative neurons from imaging in e (a.u., arbitrary units). g, Fluorescence intensity change 
(mean ± s.e.m. from baseline) as a function of post-injection time. Data were obtained from neurons (N = 58) in 4 hM3Dq-expressing mice and neurons 
(N = 30) in 2 non-hM3Dq mice. Curves represent exponential fits to the data. Asterisks represent significant difference (P < 0.01, one-way ANOVA with 
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Fig. 5 | DCZ rapidly drives activation of hM3Dq-expressing neuronal population in monkey. a, Illustration of viral vector (AAV2-CMV-hM3Dq) injection 
into one side of the amygdala. b, A coronal PET image overlaying a CT image, demonstrating that recording contacts on a multichannel electrode (shown 
on right) were located in an hM3Dq-expressing region, which was visualized as a high [11C]DCZ binding site. The high binding observed in the dorsomedial 
surface corresponds to a site of biological reaction within the recording chamber. Scale bar, 5 mm. c, Representative LFP activity changes after DCZ (left) 
and vehicle administration (right). d, Normalized gamma (40 Hz) power change (mean ± s.e.m. from baseline) 10–20 min after i.v. administration of 
reagents. Data were obtained from an hM3Dq-positive region (DCZ and vehicle; N = 27 and 26 channels, respectively, acquired across 4 sessions) and 
non-hM3Dq expressing sites (DCZ-non-hM3Dq; N = 11 channels, acquired within 1 session). Gray bars indicate baseline. Asterisk represents significant 
difference from baseline. DCZ t(26) = 7.3, P = 8.7 × 10−8; vehicle t(25) = 0.28, P = 0.78; DCZ-non-hM3Dq t(10) = 0.46, P = 0.65. e, Plots of the normalized 
power change (mean ± s.e.m. from baseline) as a function of time after vehicle or DCZ administration. The curve represents an exponential fit to the data. 
Asterisks represent a significant difference (P < 0.01, one-way ANOVA with post hoc Dunnett test) from baseline. Data were obtained from one animal.
(Fig. 6a–c). We found that FDG uptake at the hM3Dq-positive 
amygdala significantly increased after injections of 1 and 3 μg per kg 
DCZ doses (paired t-test, P < 0.01 for each dose), and this was repro-
ducible without a reduction due to repetitive activations (Fig. 6d). 
The increase of FDG uptake occurred in a dose-dependent manner 
at the hM3Dq-positive amygdala region, while uptake at the contra-
lateral control area was unchanged (one-way ANOVA, main effect 
of dose, F(2,14) = 25.06, P = 2.4 × 10−5; Fig. 6d). Voxel-wise statisti-
cal analysis further revealed a significant increase in FDG uptake 
after DCZ administration (3 μg per kg, i.v.) occurred exclusively 
at the hM3Dq-positive area (P < 0.001, uncorrected; Fig. 6b,c). In 
control monkeys without hM3Dq vector injection (non-DREADD; 
N = 2), administration of DCZ (1 or 100 μg per kg) did not change 
FDG uptake in the amygdala (one-way ANOVA, main effect of 
dose, F(2,12) = 2.29, P = 0.14; Fig. 6e). Voxel-wise statistical analy-
sis demonstrated that no significant metabolic change was detected 
throughout the entire brain following a high dose of DCZ injection 
(100 μg per kg) in control monkeys, which confirms that the 
off-target effect of DCZ is undetectable in vivo by this measure. 
These results suggest that DCZ induces a dose-dependent increase 
of chemogenetic neuronal excitation as measured by metabolic 
change with no significantly detectible off-target effects.
DCZ selectively induces behavioral deficits in hM4Di-expressing 
monkeys. Finally, we sought to modify cognitive behavior using 
inhibitory DREADDs and DCZ. We targeted the prefrontal cortex 
(PFC), especially sectors around the principal sulcus corresponding 
to Brodmann’s area 46, which is responsible for spatial working mem-
ory and executive function. To implement chemogenetic silencing, 
two monkeys received multiple injections of an AAV vector carrying 
genes encoding hM4Di (AAV1-hSyn-hM4Di-IRES-AcGFP) bilater-
ally into the dorsal and ventral banks of the principal sulcus (Fig. 7a). 
[11C]DCZ PET confirmed that in vivo hM4Di expression covered the 
bilateral target regions (Fig. 7b). We used a spatial delayed-response 
task (Fig. 7c), which is frequently employed as a sensitive probe of 
spatial working memory7,27. Compared to vehicle administration, 
i.m. administration of DCZ (100 μg per kg) significantly impaired 
the performance of the delayed-response task (two-way ANOVA
with treatment × delay, main effect of treatment, F(1,24) = 63.53, 
P = 3.4 × 10−8, and F(1,24) = 188.5, P = 7.3 × 10−13 for monkeys 229
and 245, respectively; Fig. 7d). Impairment was more severe in the
trials with longer delays (two-way ANOVA with treatment × delay, 
interaction, F(2,24) = 11.25, P = 3.6 × 10−4, and F(2,24) = 188.5, 
P = 4.3 × 10−4 for monkeys 229 and 245, respectively), which sug-
gests that it was attributable to loss of working-memory function.
Impairment of the delayed-response task appeared shortly after
administration (<10 min) and lasted for at least 2 h (t-test, P < 0.05 
for all test time periods; Fig. 7e), but disappeared at 24 h (two-way
ANOVA with treatment × delay, main effect of treatment, vehicle
versus 24 h after DCZ: F(1,24) = 0.60, P = 0.45, and F(1,24) = 0.94, 
P = 0.34 for monkeys 229 and 245, respectively; DCZ versus 24 h
after DCZ: F(1,24) = 59.48, P = 6.0 × 10−8, and F(1,24) = 171.6, 
P = 2.0 × 10−12 for monkeys 229 and 245, respectively; Fig. 7d). The
behavioral effect with DCZ was reproducible without attenuation
due to repetitive DREADD activation (Fig. 7f). Without a screen
during the delay period, DCZ did not affect the performance of the
monkey, which indicates that the impairment was unlikely attribut-
able to deficits in motor function, visual perception or general moti-
vation (Fig. 7g). We confirmed that DCZ alone did not produce any 
significant effects on spatial working memory in non-DREADD
monkeys (N = 2, including monkey 245, one of the two monkeys
that was tested before vector injection; Fig. 7h). Additional behav-
ioral examinations in three other non-DREADD monkeys using a
reward-size task further corroborated that significant side effects
of DCZ injection (100 μg per kg, i.m.) were undetectable on motor
or motivational functions (Supplementary Fig. 6). These results
demonstrate that DCZ enables a rapidly and reversibly induced
behavioral change through activating muscarinic-based DREADDs
without discernible side effects.
Discussion
Here, we report that the new DREADD agonist DCZ represents 
an extremely potent, highly brain penetrant and selective actua-
tor for hM3Dq and hM4Di DREADDs in both mice and monkeys. 
The properties of DCZ described here demonstrate that it can be 
adopted as a preferred, fast-acting chemogenetic actuator with min-
imal off-target actions, thereby enhancing opportunities for investi-
gating the causal link between neuronal activity and behavior with 
high translational potential.
Several features of DCZ indicate its superiority as a chemogenetic 
actuator over prior agonists. First, DCZ exhibits DREADD-selective 
binding both in vitro and in vivo. Radioligand binding assays dem-
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Fig. 6 | DCZ selectively induces metabolic changes in an 
hM3Dq-expressing region in a dose-dependent manner. a, Illustration of 
DREADD activation imaging with [18F]FDG. Following the administration 
of DCZ at effective doses, [18F]FDG was injected and a PET scan was 
performed to assess DREADD-induced brain metabolic changes. b, A 
coronal PET image overlaying an MR image representing specific [11C]
DCZ binding (BPND) in monkey 215. Filled and open arrowheads indicate 
the hM3Dq-expressing and control region in the amygdala, respectively. 
Scale bar, 5 mm. c, Brain areas with significantly increased [18F]FDG uptake 
after DCZ injection (3 µg per kg, N = 6 scans) compared to vehicle (N = 6) 
overlaid on an MR image template (uncorrected P < 0.001, F(1,8) > 20.25, 
one-way ANOVA within subject, monkeys 215 and 236). The significance 
level is given as an F-value represented on a color scale. d, The relationship 
between the dose of DCZ administration and standardized FDG uptake 
(SUVR) in monkeys expressing hM3Dq in the amygdala. Filled and open 
symbols are the values at hM3Dq-expressing amygdala and contralateral 
control region, respectively. *P < 0.01, paired t-test (for 1 µg per kg DCZ: 
t(3) = 6.0, P = 0.009; for 3 µg per kg DCZ: t(5) = 9.7, P = 2.0 × 10−4). 
#P < 0.05, one-way ANOVA with post hoc Tukey test (F(2,14) = 25.06, 
P = 2.4 × 10−5; vehicle versus 1 µg per kg: P = 0.013; vehicle versus 
3 µg per kg: P = 1.6 × 10−5; 1 µg versus 3 µg per kg: P = 0.03). e, Same as d, 
but for the amygdala of control monkeys without hM3Dq vector injection 
(non-DREADD monkeys 210 and 231). There was no significant dose effect 
(one-way ANOVA, F(2,12) = 2.29, P = 0.14).
demonstrated that DCZ has substantially improved selectivity com-
pared to clozapine, whereby DCZ exhibited decreased off-target 
binding while retaining similar potency at muscarinic DREADDs 
as clozapine. Second, DCZ has good brain concentration profiles 
and biostability. PET imaging revealed that systemically adminis-
tered DCZ occupied hM4Di DREADDs with a similar occupancy 
to CNO or C21 at ~20-fold or 60-fold lower doses, respectively. PK 
studies confirmed that DCZ is rapidly accumulated in mouse brains 
and monkey CSF, while its metabolites are negligible. Third, DCZ 
has high potency for muscarinic DREADDs. In vitro assays revealed 
that hM3Dq was activated by substantially lower concentrations of 
DCZ compared to CNO and C21. DCZ did not display noticeable 
agonist potencies for any of the 318 off-target GPCRs tested. Indeed, 
binding assays at a number of GPCRs, channels and transporters 
screened by the National Institute of Mental Health Psychoactive 
Drug Screening Program (NIMH PDSP) showed that DCZ had 
modest affinity (55–87 nM) for a few GPCRs, low affinity (100–
1,000 nM) for several GPCRs and minimal activity (>1,000 nM) at 
most CNS targets tested. In short, DCZ has a higher selectivity for 
DREADDs than clozapine and is capable of occupying and activat-
ing DREADDs at a lower dose than CNO and C21, thus offering a 
greater effective window than the prior DREADD ligands.
CNO has repeatedly been shown to have relatively slow kinetics 
for neuronal activation via hM3Dq. Following systemic adminis-
tration, increases in activity begin at around 5–10 min and reach 
a maximum at 45 min or later22. Because bath application of CNO 
immediately increases the firing rate of hM3Dq-expressing neu-
rons in slice preparations22, the relatively slow activation appears to 
reflect the slow kinetics of CNO uptake in the brain. Moreover, the 
major effects on DREADDs may be exerted by its metabolite clozap-
ine rather than CNO itself8, for which metabolism is non-negligeble 
in rodents8,9 and in monkeys with slower delivery (for example, sub-
cutaneous injection10). Although the concentration of metabolized 
clozapine is minimal in monkeys with rapid i.v. delivery of CNO6,28, 
the brain uptake of CNO is considerably low (Fig. 1i). In contrast, 
DCZ quickly penetrates into the brain and induces a rapid onset 
of excitability of hM3Dq-positive neuronal populations, as demon-
strated by two-photon calcium imaging in mice and by electrophysi-
ological recording in monkeys (Figs. 4 and 5). Thus, DCZ combined 
with muscarinic-based DREADDs provides a superior platform for 
examining the effects of rapid and sustainable chemogenetic neu-
ronal modulation. For example, single-unit or in vivo patch-clamp 
recording studies, for which long-term (30–60 min) maintenance 
is technically demanding, would greatly benefit from the rapid 
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Fig. 7 | DCZ selectively and rapidly induces spatial working-memory 
deficit in monkeys expressing hM4Di in the PFC. a, Illustration of the 
location of viral vector injections. AAV1-hSyn-hM4Di-IRES-AcGFP was 
bilaterally injected into the dorsal and ventral banks of the principal sulcus. 
b, A coronal parametric image of specific binding of [11C]DCZ overlaying 
an MR image in monkey 229. Open and filled arrowheads represent the 
dorsal and ventral borders of the target regions, respectively. Scale bar, 
5 mm. c, Illustration of the spatial delayed-response task. After the monkey 
was shown the baited well (Cue), the screen was placed for 0.5, 5 or 10 s 
(Delay). The monkey obtained the food if they reached for the correct food 
well and removed the cover plate (Response). d, Correct performance rates 
(mean ± s.e.m.) of the spatial delayed-response task with 0.5-, 5- and 10-s 
delays after vehicle administration (N = 5 sessions), DCZ administration 
(100 μg per kg, i.m.; N = 5) and 24 h after DCZ administration (N = 5) in 
two monkeys expressing hM4Di in the PFC. Note that monkey 245 was 
also examined before vector injection (Supplementary Fig. 6c, right). 
The behavioral testing began immediately after an i.m. administration of 
either vehicle (2% DMSO in saline) or DCZ, except for 24 h after DCZ. 
Each dot represents the data in each daily session. e, Time course of DCZ 
effects. Correct performance rates of 5- and 10-s delays as a function of 
test time for vehicle and DCZ sessions (mean ± s.e.m.; N = 5) in monkey 
229. The behavioral testings for 0–55 min and 60–115 min were conducted 
separately. Asterisks represent significant difference (t-test, P < 0.05). 
f, Correct performance rates (mean of 5- and 10-s delays) as a function 
of session number in monkeys 229 and 245. g, Correct performance 
rates of the non-memory task after vehicle (N = 5 sessions) and DCZ 
administration (100 μg per kg, i.m.; N = 5) in monkey 229. There was no 
main effect of treatment (two-way ANOVA, F(1,16) = 1.1 × 10−8, P = 1.0).  
h, There was no significant effect of DCZ for the delayed-response task 
in two control monkeys (226 and 245) without hM4Di vector injection 
(two-way ANOVA, main effect of treatment: F(1,16) = 0.03, P = 0.87 and 
F(1,16) = 1.16, P = 0.30 for monkeys 226 and 245, respectively). Correct 
performance rates with 5- and 10-s delays after vehicle (N = 5 sessions) 
and DCZ administration (100 μg per kg, i.m.; N = 5) are shown. Note that 
the data of monkey 245 were obtained before vector injection.
action would also be valuable for future therapeutic applications, for 
instance, on-demand seizure attenuation29.
The current results indicate that DCZ can also be utilized for 
in vivo neuronal silencing by activating hM4Di, an inhibitory 
DREADD. Our data suggest that a reasonable upper limit of DCZ 
dose is 100 μg per kg (Fig. 2d), which allows a sufficient concentra-
tion of DCZ to be available for hM4Di DREADD binding in vivo for 
at least 2 h in monkeys. Indeed, a 100 μg per kg dose of DCZ rapidly 
(<10 min) and reversibly induced spatial working memory defi-
cits in monkeys expressing hM4Di in the PFC (Fig. 7). Given the 
high agonist potency of DCZ (Fig. 4b), smaller DCZ doses would 
induce similar or detectable behavioral deficits. With its high selec-
tivity and potency, DCZ will provide potential orthogonality of the 
muscarinic DREADDs to other classes of chemogenetic tools2,30, 
thus providing opportunity for a multiplexed/bimodal control of 
physiological systems. Moreover, in combination with low-invasive 
targeted gene delivery methods such as ultrasonic blood–brain bar-
rier opening31, DCZ may open the potential for targeted, minimally 
invasive and side-effect-free brain theranostics.
One of the technical difficulties in chemogenetic manipulations, 
especially for large animals, is the delivery of transgene specifically 
into a target neuronal population and the accomplishment of stable 
transgene expression throughout the experimental period. Previous 
studies have shown that PET imaging with [11C]clozapine or [11C]
CNO can visualize hM4Di expression in living mice and mon-
keys, thereby providing effective tools for noninvasive monitor-
ing of gene expression6,15. However, because these ligands display 
poor DREADD selectivity or brain permeability, the application of 
DREADD–PET in monkeys was limited to visualization of hM4Di 
expression in the striatum. The present study demonstrated that 
[11C]DCZ is an exceedingly useful PET ligand for visualizing both 
hM3Dq and hM4Di expression in cortical and subcortical areas of 
mice and monkeys, with improved specificity compared to [11C]
clozapine (Fig. 1). The monitoring of transgene expression is ben-
eficial for long-term behavioral studies and is of great advantage for 
conducting successful experiments (Fig. 7). In addition to expres-
sion monitoring, PET imaging enabled the elucidation of a rela-
tionship between a pharmacologically effective dose of DREADD 
agonists and DREADD occupancy in vivo (Fig. 2d). Moreover, 
we demonstrated that [11C]DCZ PET enables the visualization of 
DREADD expression at axon terminal sites (Supplementary Fig. 2). 
This provides a powerful means for mapping projection areas for 
pathway-selective activity manipulation32, which can be induced by 
local infusion of DREADD agonist; DCZ may be suitable because of 
its high selectivity and efficacy (Fig. 1).
Although PET imaging data have implied that DCZ has 
off-target binding in cortical areas, which is possibly due to endog-
enous receptors with low affinities (Fig. 1g; Supplementary Table 
1), the agonist potency of DCZ at DREADDs is in the subnanomo-
lar range and, therefore, when used at a sufficient dose, occupancy 
on off-targets (~50 nM or higher) can be predicted to be minimal. 
Indeed, our data further suggest that systemic administration of 
DCZ at 100 μg per kg or smaller doses would not induce discernible 
off-target effects on neuronal activity or behavior in monkeys not 
expressing the muscarinic-based DREADDs (Fig. 6; Supplementary 
Fig. 6). Since the variability of CSF concentration across subjects 
and the amount of metabolites for DCZ were much smaller than 
those for CNO6 (Fig. 3a), the potential baseline sensitivity to DCZ 
would be minimal. Therefore, DCZ provides a clear advantage over 
prior agonists due to its increased reliability (that is, there are mini-
mal concerns about potential off-target effects). However, we can-
not completely rule out unanticipated off-target effects because it is 
impossible to measure the activity of DCZ against every potential 
endogenous target. Therefore, as with all other neuromodulation 
technologies, control experiments—here using non-DREADD ani-
mals—are recommended. In mice, control experiments are essential 
since the current study did not examine an off-target action of DCZ 
at a high dose; that is, C21, a DCZ metabolite, was detected at very 
low concentrations in CSF (<0.2 nM; Fig. 3c). Future studies will be 
required to determine appropriate DCZ doses and the effective time 
window for mouse chemogenetic experiments.
In conclusion, the characteristics of DCZ described here—its 
high selectivity, high brain penetrability and biostability—facilitate 
the rapid and selective modulation of neuronal activity and behav-
ior with muscarinic-based DREADDs in living animals. Given the 
potential drawbacks of prior DREADD agonists, DCZ will pro-
vide clear benefits for many users of muscarinic DREADDs, with 
increased reliability due to removing concerns about potential 
off-target responses.
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Methods
Subjects. All experimental procedures involving animals were carried out in 
accordance with the Guide for the Care and Use of Laboratory Animals (National 
Research Council of the US National Academy of Sciences) and were approved 
by the Animal Ethics Committee of the National Institutes for Quantum and 
Radiological Science and Technology.
A total of 16 macaque monkeys (7 rhesus (Macaca mulatta) and 9 Japanese 
monkeys (Macaca fuscata); 11 males, 5 females; 2.8–8.0 kg; age 4–10 years) 
were used (a summary of the subjects used in the experiments is provided in 
Supplementary Table 2). The monkeys were kept in individual primate cages in 
an air-conditioned room. A standard diet, supplementary fruits/vegetables and a 
tablet of vitamin C (200 mg) were provided daily.
Adult hM4Di transgenic mice with C57BL/6j background15 (male, age >12 
weeks) and age-matched non-transgenic littermates or wild-type C57BL/6j mice 
(male, age >12 weeks; Japan SLC) were used. All mice were maintained in a 12-h 
light–dark cycle with ad libitum access to standard diet and water.
Viral vector production. AAV2 (AAV2-CMV-hM4Di, AAV2-CMV-KORD, 
AAV2-CMV-hM3Dq, AAV2-CMV-AcGFP; Figs. 1d, 4c and 5a) and AAV1 
(AAV1-hSyn-hM4Di-IRES-AcGFP; Fig. 7a) vectors were produced using 
a helper-free triple transfection procedure and were purified by affinity 
chromatography (GE Healthcare). Viral titers were determined by quantitative 
PCR using Taq-Man technology (Life Technologies). The transfer plasmid was 
constructed by inserting a complementary DNA fragment and the WPRE sequence 
into an AAV backbone plasmid (pAAV-CMV, Stratagene). For production of an 
AAV-DJ vector (AAV-DJ-rSyn-GCaMP6s), a transfer plasmid containing the rat 
Synapsin promoter and cDNA encoding GCaMP6s (Addgene plasmid number 
40753) was assembled and transfected with helper-free DJ plasmids (Cell Biolabs). 
Viral particles were purified using a HiTrap heparin column (GE Healthcare). Viral 
titers were determined using an AAVpro Titration kit ver2 (Takara).
Surgical procedures and viral vector injections. In monkeys, surgeries were 
performed under aseptic conditions in a fully equipped operating suite. We 
monitored body temperature, heart rate, SpO2 and tidal CO2 throughout all 
surgical procedures. Monkeys were immobilized by i.m. injection of ketamine 
(5–10 mg per kg) and xylazine (0.2–0.5 mg per kg) and intubated with an 
endotracheal tube. Anesthesia was maintained with isoflurane (1–3%, to effect). 
Before surgery in monkeys, magnetic resonance (MR) imaging (7 tesla 400 mm/
SS system, NIRS/KOBELCO/Brucker) and X-ray CT scans (Accuitomo170, J. 
Morita) were performed under anesthesia (continuous infusion of propofol 0.2–
0.6 mg per kg per min, i.v.). Overlay MR and CT images were created using PMOD 
image analysis software (PMOD Technologies) to estimate stereotaxic coordinates 
of target brain structures.
For subcortical injections, monkeys underwent a surgical procedure to 
open burr holes (~8 mm in diameter) for the injection needle. Viruses were 
pressure-injected using a 10-µl Hamilton syringe (model 1701 RN, Hamilton) with 
a 30-gauge injection needle and a fused silica capillary (450-µm outside diameter) 
to create a ‘step’ about 500-µm away from the needle tip to minimize backflow. The 
Hamilton syringe was mounted into a motorized microinjector (Legato130, KD 
Scientific or UMP3T-2, WPI) that was held by a manipulator (model 1460, David 
Kopf) on the stereotaxic frame. After the dura mater was opened about 3 mm, 
the injection needle was inserted into the brain and slowly moved down 2 mm 
beyond the target and then kept stationary for 5 min, after which it was pulled up 
to the target location. The injection speed was set at 0.25–0.5 µl min–1. After each 
injection, the needle remained in situ for 15 min to minimize backflow along the 
needle. Monkeys 209 and 212 had co-injections of AAV vectors (total 6 µl; 3 µl × 2 
different depths in a track) carrying the hM4Di construct (AAV2-CMV-hM4Di; 
1.8 × 1013 (monkey 209) and 2.6 × 1013 (monkey 212) particles per ml) and AcGFP 
genes (AAV2-CMV-AcGFP; 0.7 × 1013 particles per ml) in one side of the putamen 
and co-injections of AAV vectors (total 6 µl; 3 µl × 2 different depths in a track) 
carrying κ-opioid-based DREADD construct (AAV2-CMV-KORD; 1.8 × 1013 
particles per ml) and AcGFP (AAV2-CMV-AcGFP; 0.7 × 1013 particles per ml) in 
the other side. Monkeys 214, 215, 233 and 236 had co-injections of AAV vectors 
(total 6 µl; 3 µl × 2 tracks, 2-mm apart rostrocaudally) carrying the hM3Dq 
construct (AAV2-CMV-hM3Dq; 1.2 × 1013 particles per ml) and AcGFP genes 
(AAV2-CMV-AcGFP; 0.7 × 1013 particles per ml) into the left (monkeys 214 and 
215) or right (monkeys 233 and 236) amygdala.
Monkeys 229 and 245 had AAV1-hSyn-hM4Di-IRES-AcGFP (3.8 × 1013 
particles per ml) injected into the bilateral PFC (Brodmann’s area 46). After retracting 
the skin and galea, the frontal cortex was exposed by removing a bone flap and 
reflecting the dura mater. Handheld injections were made under visual guidance 
through an operating microscope (Leica M220, Leica Microsystems), with care taken 
to place the beveled tip of the Hamilton syringe containing the viral vector at an 
oblique angle to the brain surface. One person inserted the needle into the intended 
area of injection and another person pressed the plunger to expel approximately 1 µl. 
Nine tracks were injected in each hemisphere; one was located 1-mm posterior to 
the caudal tip of the principal sulcus, and the others were located along the dorsal (4 
tracks) and ventral (4 tracks) bank of the principal sulcus posterior to the rostral tip 
of the ascending limb of the arcuate sulcus  
(Fig. 7a). Viral vectors were injected at 3–5 µl per track depending on the depth. Total 
amounts of viral aliquots injected into the right and left hemispheres were 35 and 
37 µl, respectively, for monkey 229, and 44 and 40 µl, respectively, for monkey 245.
In mice, the animals were anesthetized with a mixture of air, oxygen and 
isoflurane (3–5% for induction and 2% for surgery) via a facemask, and a cranial 
window (3–4 mm in diameter) was placed over the left somatosensory cortex, 
centered at 1.8-mm caudal and 2.5-mm lateral from the bregma, according 
to the Seylaz–Tomita method33. On the day of cranial window surgery, AAV 
vectors carrying genes encoding GCaMP6 (AAV-DJ-rSyn-GCaMP6; 3.5 × 1011 
particles per ml) and the hM3Dq construct (AAV2-CMV-hM3Dq; 1.5 × 1013 
particles per ml) were co-injected into the barrel cortex using glass needles. A 
custom metal plate was affixed to the skull with a 7-mm-diameter hole centered 
over the cranial window. The method for preparing the chronic cranial window has 
previously been reported in detail34.
Radioligand competition binding assays. Radioligand binding assays with 
membrane preparations to determine binding affinity were carried out by the 
NIMH PDSP (https://pdsp.unc.edu/). Detailed assay protocols are available at the 
NIMH PDSP website (https://pdsp.unc.edu/pdspweb/?site=assays). NIMH PDSP 
is directed by B.L.R., University of North Carolina at Chapel Hill, North Carolina, 
and Program Officer J. Driscoll at NIMH, Bethesda, USA.
BRET experiments. HEK293T cells split into 10-cm plates and maintained 
in DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin–streptomycin (pen–strep) were co-transfected with 1 μg each of hM3D 
or hM4D and Gαq-RLuc8 or Gαi1-RLuc8, respectively, and 1 μg each of Gβ1 and 
Gγ2–GFP2 using TransIT-2020 (Mirus) as the transfection reagent. For negative 
controls, 1 μg of pcDNA was transfected in place of hM3D or hM4D. After at least 
12 h, cells were plated in poly-d-lysine-coated white 96-well microplates (Greiner) 
in 100 μl of DMEM supplemented with 1% dialyzed FBS and 1% pen–strep at 
a density of 50,000 cells per well. After at least an additional 12 h, media were 
aspirated and replaced with 60 μl of assay buffer (1× Hanks’ balance salt solution 
(HBSS), 20 mM HEPES buffer, pH 7.40). Next, 10 μl of 50 μM coelenterazine 400a 
(NanoLight Technology) was added. After a 5-min incubation, 30 μl of 3× drug 
(in assay buffer containing 0.3 mg ml–1 ascorbic acid and 0.3% BSA) was added. 
After an additional 5-min incubation, plates were read for luminescence with 
a Mithras LB 940 multimodal microplate reader (Berthold Technologies). Data 
were analyzed by GraphPad Prism 7.0 using the built-in dose–response function 
and were normalized to the responses produced by CNO. In the presence of 
RLuc8 substrate coelenterazine, proximal and properly oriented alpha-RLuc8 
and gamma–GFP2 produce BRET that reflects the equilibrium association of 
the heterotrimeric G protein under a given set of conditions. Dissociation of the 
heterotrimer consequent to receptor activation decreases BRET, and the extent 
of this decrease is dose-dependent. Since this assay directly measures G-protein 
dissociation, which is the most proximal signaling event downstream of GPCR 
activation, measurements made by this assay are relatively insensitive to receptor 
reserve and signal amplification (see Olsen et al.20 for details regarding BRET 
assays and construct design).
In vitro cAMP assays. Gi-mediated inhibition of cAMP production assays were 
performed in transiently transfected HEK293T cells. Briefly, HEK293T cells, 
transfected overnight with GloSensor plasmid (Promega) and receptor DNAs, were 
plated (10–15,000 cells per 40 μl per well) in poly-l-lysine-coated white 384-well 
clear-bottom cell culture plates in DMEM with 1% dialyzed FBS. After 16–20 h, 
cells were removed from medium and stimulated with ligands prepared in HBSS, 
20 mM HEPES, 0.1% BSA, pH 7.4, for 15 min, followed by 0.1 μM isoproterenol 
(final concentration) in GloSensor reagent. Luminescence was read on a  
Wallac TriLux Microbeta counter (PerkinElmer). Results were normalized  
to the CNO activity and analyzed using the built-in dose–response function in 
GraphPad Prism 7.0.
In vitro calcium mobilization (FLIPR) assays. HEK293T cells stably expressing 
hM3Dq or hM3 receptors were used for Gq-mediated calcium mobilization 
assays. Assays were performed according to published procedures12. More detailed 
assay protocols are available at the NIMH PDSP website (https://pdsp.unc.edu/
pdspweb/?site=assays).
GPCRome screening (PRESTO-Tango) assays. Potential agonist activity at the 
human GPCRome was measured using the PRESTO-Tango assay as previously 
described21.
Brain protein-binding assays. The unbound fraction of DCZ in brain tissue 
was measured using an equilibrium dialysis method. PBS solutions containing 
mouse brain homogenates (20%) and DCZ (final concentrations of 10, 100 or 
1,000 nM) were added to 96-well plates (Equilibrium Dialyzer MW10K; Harvard 
Apparatus), followed by equilibrium dialysis (22 h at 37 °C). A certain amount of 
methanol solution containing sulfaphenazole was added as an internal standard to 
the separated filtrate, brain homogenate fractions and pre-dialyzed samples, and 
centrifuged (1,700 × g, 10 min). The supernatant fractions were applied to liquid 
chromatography with tandem mass spectrometry (LC–MS/MS) to measure the 
DCZ concentration. The average fraction of unbound brain tissue was calculated 
for each concentration, as reported in a previous publication35.
Drug administration. DCZ (HY-42110, MedChemExpress or synthesized 
in-house, see below) was dissolved in 1–2% dimethyl sulfoxide (DMSO) in 
saline to a final volume of 0.1 ml per kg. CNO (Toronto Research) was dissolved 
in 2.5% DMSO in saline to a final volume of 0.1 ml per kg. C21 (Tocris) was 
dissolved in 2% DMSO in distilled water to a final volume of 0.1 ml per kg. For 
plasma/CSF analysis, a 23-gauge catheter was placed in the saphenous vein or 
the spinal canal for acute sampling while the monkey was under ketamine and 
xylazine anesthesia. DCZ (100 μg per kg) was administered at a rate of 0.2 ml s–1 
intravenously via catheter. For PET blocking and occupancy studies, DCZ (10, 30, 
100 or 1,000 μg per kg), CNO solution (100, 300, 1,000, 3,000 or 10,000 μg per kg) or 
C21 (300, 1,000 or 6,000 μg per kg) was administered intravenously via a saphenous 
vein catheter 1–15 min before PET imaging. For the FDG–PET study, DCZ (1, 3 or 
100 μg per kg) solution or vehicle was administered intravenously 1 min before PET 
imaging. Fresh solutions were prepared on the day of usage.
Synthesis of DCZ. 1-Methylpiperazine (0.33 ml, 2.97 mmol) was added to a 
solution of 11-chloro-5H-dibenzo[b,e][1,4]diazepine (0.22 g, 0.96 mmol)12 in 
toluene (5 ml). The resulting solution was refluxed for 2 h. After cooling down 
to room temperature, the reaction was concentrated. The resulting residue 
was purified by silica gel flash column chromatography with 0−10% methanol 
in dichloromethane to give the desired product (0.20 g, yield 70%). 1H NMR 
(800 MHz, CD3OD) δ: 7.69–7.64 (m, 2H), 7.41 (d, J = 7.9 Hz, 1H), 7.33–7.29  
(m, 2H), 7.27 (t, J = 7.6 Hz, 1H), 7.19–7.13 (m, 2H), 4.40–3.80 (br, 4H), 3.80–3.50 
(br, 4H), 3.06 (s, 3H). HRMS calculated for C18H21N4: 293.1761; found: 293.1720 
[M + H]+.
Radiosynthesis. [11C]DCZ was produced as follows. An automated multipurpose 
synthesizer developed in-house was used for the radiosynthesis. The 
cyclotron-produced [11C]CO2 was converted to [11C]CH3I, which was distilled 
and sent through a silver trifluoromethanesulfonate glass tube under N2 gas flow 
to yield [11C]methyl trifluoromethanesulfonate ([11C]CH3OTf). [11C]CH3OTf was 
then introduced to a reaction vial containing desmethyl precursor (C21, 0.2 mg) 
in dichloromethane (0.3 ml) under room temperature. The reaction mixture was 
kept at room temperature for 5 min. high-performance LC (HPLC) purification 
was completed on an X-Bridge C18 column (10 mm inner diameter × 250 mm, 
Waters) using CH3CN/H2O/Et3N (acetonitrile/water/triethylamine) (40/60/0.1%) 
at 5.0 ml min–1. The radioactive fraction corresponding to [11C]DCZ (tR: 9.5 min) 
was collected and formulated to obtain an injectable solution. Synthetic time was 
about 40 min from the end of bombardment with an averaged radiochemical yield 
(decay-corrected) of 76.2% based on [11C]CO2 (N = 16). Radiochemical purity was 
assayed by analytical HPLC (column: Capcell Pak C18 UG120 S5, 4.6-mm inner 
diameter, 150-mm length; Shiseido) ultraviolet detector at 254 nm; mobile phase of 
CH3CN/H2O (40/60) (Et3N 0.1%). Radiochemical purity and molar activity of [11C]
DCZ were >98% and 130 ± 45 GBq μmol–1 (N = 16), respectively.
[11C]clozapine was radiosynthesized from desmethylclozapine by 
11C-methylation using 11C-methyl triflate based on a previously described 
protocol36, and its radiochemical purity and specific radioactivity at the end of 
synthesis exceeded 95% and 37 GBq μmol–1, respectively. [18F]FDG was purchased 
from Nihon Medi-Physics.
PET imaging. PET scans were performed using a microPET Focus 220 scanner 
(Siemens Medical Solutions USA). Anesthesia was performed as follows: a mouse 
was anesthetized with 1–3% isoflurane and a monkey was immobilized by i.m. 
injection of ketamine (5–10 mg per kg) and xylazine (0.2–0.5 mg per kg) and then 
maintained in an anesthetized condition with isoflurane (1–3%) during all PET 
procedures. Transmission scans were performed for about 20 min with a Ge-68 
source for monkey scans. Emission scans were acquired in three-dimensional (3D) 
list mode with an energy window of 350–750 keV after i.v. bolus injection of [11C]
DCZ (31.8–46.4 MBq for mice and 276.9–386.9 MBq for monkeys), [11C]clozapine 
(287.4–353.8 MBq), [11C]CNO (354.6 MBq) or [18F]FDG (157.6–358.5 MBq). The 
actual injected dose depended on the specific radioactivity and the weight of the 
subjects (for example, <0.8 µg per kg for monkey 209). Emission data acquisition 
lasted 90 min for [11C]DCZ, [11C]clozapine and [11C]CNO scans and 120 min 
for [18F]FDG scans. All list-mode data were sorted into 3D sinograms, which 
were then Fourier-rebinned into two-dimensional sinograms (frames × minutes: 
5 × 1, 5 × 2, 5 × 3 and 12 × 5 for [11C]DCZ and [11C]clozapine, 24 × 5 for [18F]
FDG). Images were thereafter reconstructed with filtered back-projection 
using a Hanning filter cut-off at a Nyquist frequency (0.5 mm–1). SUVs were 
calculated using PMOD image analysis software as the regional concentration 
of radioactivity averaged across the specific time window after injection of the 
radioligand. Volumes of interest (VOIs) were placed using PMOD image analysis 
software with reference to the MR image of individual monkeys or the mouse 
brain template generated as previously described15. To obtain accurate registrations 
between PET and MR images, the rigid matching function of PMOD (PFUS) 
was used. For this PET–MR registration, maximum errors in translation and 
rotation of human brain data were 1.67 mm and 0.6°, respectively37, despite the 
fact that no data were available for monkey brains. In addition to the registration 
error, there should be spatial limitation of PET imaging of the ‘positive region’ 
due to the signal spread from the source. Based on our in vivo and in vitro cross 
reference, we approximated that the limitation was <2 mm. In FDG studies of 
hM3Dq-expressing monkeys, the VOI for the hM3Dq-positive region was defined 
as the area where the BPND value of [11C]DCZ was higher than 1.0, while that of the 
control region was placed at the corresponding contralateral side.
Two-photon laser-scanning microscopy. Awake mice were placed on a 
custom-made apparatus, and real-time imaging was conducted by two-photon 
microscopy (TCS-SP5 MP, Leica Microsystems) with an excitation wavelength 
of 900 nm. An emission signal was separated by a beam splitter (560/10 nm) 
and simultaneously detected with a band-pass filter for SR101 (610/75 nm) and 
GCaMP6 (525/50 nm). A single image plane consisted of 512 × 512 pixels, and the 
in-plane pixel size was 0.9 µm × 0.9 µm. The methods for functional imaging using 
two-photon microscopy have been reported in detail38. Briefly, continuous image 
capturing was conducted for neurons on the surface over the barrel cortex at a 
rate of 0.25 s per frame for 60 s with a 512 × 512 pixel field of view. The percentage 
change in green fluorescence of neurons was manually measured offline with 
LAS AF software (Leica Microsystems). Sensory-evoked neuronal excitation was 
examined by means of whisker stimulation as previously reported38. Air puff 
stimulations (15 p.s.i., 50-ms pulse width, 10 s duration, 10 Hz) were given to 
whiskers on the contralateral side of scanning 4 times in a day.
Electrophysiology. Electrophysiological recordings were performed on one 
monkey while seated in a monkey chair with its head fixed via a headpost, 
and maintained under an anesthetized condition with i.v. infusion of propofol 
(20 mg per kg per h). LFPs were recorded using a multicontact linear probe with 
12 recording contacts separated by 150 μm (Axial Array, FHC). The probe was 
inserted into the brain with a hydraulic micromanipulator (MO-97A, Narishige) 
guided with a stainless steel tube and an implanted recording chamber system 
(Crist Instruments). Chamber grids were either purchased from Crist Instruments 
or custom-made with a 3D printer (Object260 Connex3, Stratasys). For every 
recording session, the monkey was CT scanned before the recording probe was 
removed. The electrode location relative to hM3Dq expression was confirmed by 
aligning the CT image with the pre-acquired PET image on PMOD. The probe 
was connected to a multichannel acquisition system (System 3, Tucker-Davis 
Technologies) running on a Windows PC. For LFPs, the signals were band-pass 
filtered between 1.5 Hz and 500 Hz, and sampled at 3 kHz. LFP signals were further 
analyzed only when multiunit waveforms were qualitatively observed in a high 
frequency band (that is, 400 Hz to 5 kHz) at the corresponding recording sites. The 
spectral component of the LFP signal was analyzed with Matlab (MathWorks). The 
spectral power of each frequency was computed using a short-time fast Fourier 
transform algorithm within a 60-s window sliding in 30-s steps. The change in 
the gamma band power (40 Hz) and its change relative to that in a 3- or 10-min 
pre-injection period was quantified. The spectrogram was smoothed with a 
Hanning window with 4.3-min half-maximum width for display reasons.
Behavioral testing. Monkeys 226, 229 and 245 were tested with a spatial 
delayed-response task (Fig. 7c). The protocol was based on previous studies using 
the Wisconsin general testing apparatus39,40. Behavioral testing was conducted in a 
sound-attenuated room. Monkeys were seated in a monkey chair from which they 
could reach out one hand and take food to their mouths. A wooden table with two 
food wells was placed in front of the monkeys, and a screen was placed between 
the monkeys and the table. First, a piece of food reward (raisin or half peanut) was 
placed in one of the two food wells, and then both wells were covered with wooden 
plates. Then, the screen was placed for 0.5, 5 or 10 s, which served as delay periods 
(0.5-s delay was not introduced for non-DREADD monkeys). The position of the 
baited well (left or right) was pseudorandomly determined. After the delay period, 
the screen was removed and the monkeys were allowed to select either food well 
to get the food. The monkeys were allowed to take the food if they reached for 
the correct food well and removed the cover plate. The inter-trial interval was set 
at 10–15 s. A daily session lasted about 1 h and consisted of 3–4 blocks of 20–30 
trials, which were interleaved by a 5-min rest period. The behavioral testing began 
immediately or 1 h after an i.m. administration of either vehicle (2% DMSO in 
saline) or DCZ (100 μg per kg), and was conducted on the next day (24 h later) of 
the DCZ administration. One of the monkeys injected with AAV-hM4Di in the 
bilateral PFC (monkey 229) was also tested in a non-memory control task, which 
was almost the same as the delayed response task except that the screen was not 
placed during the delay period and that the 0.5-s delay was not introduced.
Three monkeys without AAV injections (non-DREADD; monkeys 224, 228 
and 230) were tested with a reward-size task (Supplementary Fig. 6a) using the 
same protocol as applied in a previous study41. The behavioral testing began 
10 min after an i.m. administration of either vehicle (2% DMSO in saline) or DCZ 
(100 μg per kg).
Histology and immunostaining. The monkeys were deeply anesthetized with an 
overdose of sodium pentobarbital (80 mg per kg, i.v.) and transcardially perfused 
with saline at 4 °C, followed by 4% paraformaldehyde in 0.1 M PBS, pH 7.4. 
The brains were removed from the skull, post-fixed in the same fresh fixative 
overnight, saturated with 30% sucrose in phosphate buffer (PB) at 4 °C, and then 
cut serially into 50-μm-thick sections on a freezing microtome. For visualization 
of immunoreactive signals of hM4Di, a series of every sixth section was immersed 
in 1% skim milk for 1 h at room temperature and incubated overnight at 4 °C with 
rabbit anti-M4 polyclonal antibody (1:200; H-175, Millipore) in PBS containing 
0.1% Triton X-100 and 1% normal donkey serum for 2 days at 4 °C. The sections 
were then incubated in the same fresh medium containing biotinylated donkey 
anti-rabbit IgG antibody (1:1,000; Jackson ImmunoResearch) for 2 h at room 
temperature, followed by avidin–biotin–peroxidase complex (ABC Elite, Vector 
Laboratories) for 2 h at room temperature. For visualization of the antigen, 
the sections were reacted in 0.05 M Tris-HCl buffer (pH 7.6) containing 0.04% 
diaminobenzidine (DAB), 0.04% NiCl2 and 0.003% H2O2. The sections were 
mounted on gelatin-coated glass slides, air dried and cover-slipped. A part of other 
sections was Nissl stained with 1% Cresyl violet. The same protocol was used for 
visualization of immunoreactive signals of hM3Dq with rabbit anti-M3 polyclonal 
antibody (1:200; HPA024106, Atlas Antibodies).
The mice were deeply anesthetized with sodium pentobarbital and then 
transcardially perfused with PBS. Brain tissues were removed and fixed with 4% 
paraformaldehyde in PB overnight, followed by cryoprotection with 30% sucrose in 
PB. Frozen sections (10-μm thick) were generated using a cryostat (HM560; Carl 
Zeiss). Visualization of immunoreactive signals of hM4Di was performed using 
an anti-M4 antibody (H-175) and fluorophore-conjugated secondary antibodies 
(Invitrogen) as previously described15.
Images of sections were digitally captured using an optical microscope 
equipped with a high-grade charge-coupled device camera (Biorevo, Keyence).
PK analysis. Four monkeys and 15 mice were used to assess the concentration 
of DCZ and its metabolites in plasma, CSF or brain. In monkeys, blood and CSF 
were collected at 15, 30, 45, 60, 75, 90, 105 and 120 min after DCZ administration 
(100 μg per kg, i.v. or i.m.) under ketamine and xylazine anesthesia. In mice, after 
i.p. injection of DCZ (100 μg per kg), blood and brain samples were collected at 5, 
30, 60, 120 min or 24 h, and CSF was collected at 30 and 120 min. Mouse blood was 
collected by heparinized syringes via the heart under isoflurane anesthesia followed 
by centrifugation at 10,000 × g for 5 min to obtain plasma samples, and brains were 
removed and frozen by liquid nitrogen immediately after blood collection. All 
samples were stored at –80 °C until analysis.
The protocols for sample pretreatment of CSF and plasma have been previously 
described6. Mouse brains were homogenized in 2-brain-weight water. An 
acetonitrile solution (0.8 ml) containing granisetron (0.5 ng ml–1) as an internal 
standard was added to the brain homogenate (0.2 ml), followed by centrifugation 
at 10,600 × g for 2 min at 4 °C. The supernatant was collected and filtered through 
a solid-phase extraction column (Phree, Shimadzu). The filtrate was dried under 
nitrogen gas at 40 °C and redissolved in 5% acetonitrile (0.2 ml) followed by 
sonication for 30 s and centrifugation (500 × g) for 2 min. The supernatant was 
filtered through a solid-phase extraction column again before its application to 
LC–MS/MS.
Quantification of C21, DCZ and DCZ-N-oxide was performed by multiple 
reaction monitoring using a Shimadzu UHPLC LC-30AD system (Shimadzu) 
coupled to a tandem MS AB Sciex Qtrap 6500 system (AB Sciex). The following 
multiple reaction monitoring transitions (Q1/Q3) were used to monitor each 
compound: C21 (279.0/193.0), DCZ (293.0/236.0), DCZ-N-oxide (309.0/192.9) 
and granisetron (313.2/138.1). Other protocols have been previously described6.
Statistical analyses. In vitro assays. All data were analyzed using GraphPad Prism 
7. Inhibition binding data were analyzed according to a one-site binding model, 
and the equilibrium dissociation constant (Kd) values of unlabeled ligands were 
calculated by constraining the radioligand Kd values to the values estimated 
from saturation binding assays. Concentration–response curves were fitted to a 
three-parameter logistic equation. All affinity and potency values were estimated 
as logarithms.
PET imaging. To estimate the specific binding of [11C]DCZ, the regional binding 
potential relative to nondisplaceable radioligand (BPND) was calculated using 
PMOD with an original multilinear reference tissue model (MRTMo)42 as 
described by the following equation:
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where C(t) and C′(t) are the regional or voxel time–radioactivity concentrations 
in the tissue and reference regions, respectively (kBq ml–1), V and V′ are the 
corresponding total distribution volumes (ml/ml), k2′ (min–1) is the clearance rate 
constant from the reference region to plasma, and b is the intercept term, which 
becomes the constant for T > t*. In this study, t* was determined as 2 min for the 
mouse studies and 15 min for the monkey studies. Equation 1 allows estimation 
of three parameters, β1 = V/V′, β2 = V/(V′k2′) and β3 = b by multilinear regression 
analysis for T > t*. Assuming that the nondisplaceable distribution volumes in 
tissue and reference regions are identical, BPND (BPND = V/V′ – 1) is calculated from 
the first regression coefficient as BPND = (β1 – 1).
Estimates of fractional occupancy (Occ) were calculated using the following 
equation:
Occ ¼ hM4DiBPBL � hM4DiBPPT
 
= hM4DiBPBL � CONBPBL
 
ð2Þ
where hM4DiBPBL and CONBPBL indicate BPND at the hM4Di-expressing putaminal 
region and control putamen under baseline conditions, respectively, while hM4DiBPPT 
indicates BPND at the hM4Di-expressing putaminal region under the pretreatment 
condition. The relationship between occupancy and agonist dose (Dagonist) was 
modeled using the Hill equation as follows:
Occ ¼ Dnagonist=ðDnagonist þ EDn50Þ ð3Þ
where ED50 and n indicate the agonist dose achieving 50% occupancy and the Hill 
coefficient, respectively.
For FDG–PET analysis, dynamic SUV images were motion corrected and then 
were averaged between 30 and 60 min after injection of the radioligand. Voxel-wise 
statistical analyses were performed using SPM12 software (Wellcome Department 
of Cognitive Neurology, London, UK; www.fil.ion.ucl.ac.uk) and Matlab R2016a 
(MathWorks). We used a total of 12 scans including vehicle and DCZ 3 μg per kg 
pretreatment conditions to detect the metabolic change by hM3Dq activation and a 
total of 12 scans including vehicle and DCZ 100 μg per kg pretreatment conditions 
to examine the effect of off-target actions in the non-DREADD monkeys. The 
averaged SUV images were spatially normalized into a standard template brain 
MR image43 after co-registration of individual MR images. The resulting images 
were smoothed with a 2.6-mm Gaussian filter and then extracted using a brain 
mask. The SUVs for each scan were corrected using grand mean scaling and by 
analysis of covariance for global normalization. Subsequently, one-way ANOVA 
within subject was applied. The statistical threshold was set at uncorrected 
P < 0.001 (F(1,8) > 20.25) and an extent of 100 contiguous voxels per cluster. For 
the VOI-based analysis, we used a total of 17 scans from hM3Dq-expressing 
monkeys including vehicle and 1 and 3 μg per kg DCZ pretreatment conditions, 
and a total of 16 scans from non-DREADD monkeys including vehicle and 1 
and 100 μg per kg DCZ pretreatment conditions. The SUVs were obtained using 
PMOD and then were normalized by whole-brain value. Paired t-test was used to 
detect the metabolic change by hM3Dq activation in each condition. To examine 
the dose-dependency or off-target actions, one-way ANOVA followed by post hoc 
Tukey–Kramer test was performed.
Neuronal activity. Time-dependent changes in fluorescence signals and LFP power 
were analyzed according to a one-phase exponential association model using 
GraphPad Prism 7. Repeated-measures ANOVA followed by post hoc Dunnett test 
was used to examine differences between baseline and drug-evoked mean neural 
signals. The signals were displayed after normalization to the baseline levels, but 
statistical tests were conducted on the original data.
To examine the long-term effect of hM3Dq activation on normal neuronal 
responsiveness, the fluorescence signal change within 0.2–10.2 s after whisker 
stimulation onset was averaged across 4 trials and compared using pairwise t-test. 
DCZ-induced fluorescence signal changes at 10 min after the first and second DCZ 
administrations were compared by pairwise t-test. The second DCZ administration 
was applied 24 h after the first.
Behavioral testing. To examine the effect of DCZ on the performance of the 
delayed-response task, behavioral measurement (correct rates) was subjected 
to two-way ANOVA (treatment × delay) and post hoc t-test with Bonferroni 
correction using GraphPad Prism 7. To examine whether the performance was 
recovered at 24 h after DCZ administration, the same procedures were conducted 
between DCZ and post-DCZ, and vehicle and post-DCZ sessions. To examine the 
effect of DCZ treatment on the behavior in test time, the data of 5- and 10-s delays 
were pooled and then compared between treatment conditions by t-test.  
To examine the effect of DCZ on the performance of the reward-size task, reaction 
times and error rates were subjected to two-way ANOVA (treatment × reward size). 
The total correct trial number for each session was subjected to two-way  
ANOVA (treatment × subject). For each analysis, effect size eta-squared (η2) was 
calculated using R.
General data collection and statistical statements. Data collection and analyses 
were not performed blinded to the conditions of the experiments, except for 
the in vitro studies, which were blinded. For in vivo experiments, the order of 
drug administration (for example, DCZ or vehicle) was pseudorandom and 
shuffled across animals. No samples were excluded from the analysis. Statistical 
tests included parametric and nonparametric methods. All statistical tests were 
two-sided unless specifically stated otherwise. In some statistical tests, data 
distributions were assumed to be normal and/or with equal variances, but this was 
not formally tested. No statistical methods were used to predetermine sample sizes, 
but our sample sizes were similar to those reported in previous publications (for 
example, see refs. 5–8,10,30).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the 
corresponding authors upon reasonable request.
Code availability
The code to generate the results and the figures of this study are available from the 
corresponding authors upon reasonable request.
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